RevOpsis Therapeutics, founded in 2022 and based in Springfield, Illinois, is dedicated to combating vision loss through innovative bispecific antibody technology. Utilizing their proprietary Rev-Mod Platform, the company focuses on the rapid discovery and development of novel therapies aimed at treating a variety of ocular conditions. Their core mission is to improve disease outcomes and extend remission by targeting key biological pathways in complex multifactorial diseases.
Notable figures affiliated with RevOpsis Therapeutics include leading scientists and industry experts in the field of biologics and ophthalmology. The company has garnered attention from prominent investors in the biotech sector, contributing to its swift advancements. Key achievements include the development of multiple therapeutic candidates that show promise in preclinical trials. RevOpsis Therapeutics is poised to make a significant impact on the treatment of vision loss, potentially transforming the landscape of ocular therapeutics.
Quick Facts
When was RevOpsis Therapeutics' last funding round?
RevOpsis Therapeutics' most recent funding round was for $16.5M (USD) in April 2024.
How much disclosed funding has RevOpsis Therapeutics raised?
As of Apr 25, 2024, RevOpsis Therapeutics has disclosed funding of $24.4M (USD).
